Thrombogenics
Thrombogenics
1,77 %
6,900 EUR
0,12
Kurs
6,900
Hög
6,970
Förändring
1,77 %
Låg
6,760
Uppdaterad
2018-09-07
Öppen
6,840
Factsheet for Thrombogenics
Company Profile
Description
Oxurion NV is a Belgium based biopharmaceutical company. The company is focused on developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has developed a diverse portfolio of disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. It owns the global rights to Jetrea (ocriplasmin), the pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).
Key Stats
Website: https://www.oxurion.com
Headquarter country: Belgium
Employees: 154
Market Cap (at close 22-07-2019): EUR 226M
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 5,60 12,80
Forward Price/Earnings 4,60
Price/Free Cash Flow 8,50 16,60
Return on Assets -29,00 16,80 -40,10 -19,00 -20,80
Return on Equity -32,40 18,80 -43,10 -20,00 -21,90
Return on Invested Capital -32,50 18,80 -43,20 -20,20 -22,30
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 5,32 9,06 7,10 11,20 13,78
Gross Profit 0,00 0,01 0,00 0,01 0,01
Gross Margin % 36,94% 71,52% 3,15% 71,16% 66,61%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -35,00 26,00 -26,00 -30,00 -43,00
Net income -38,00 23,00 -60,00 -38,00 -51,00
Basic Earnings Per Share -1,01 0,63 -1,67 -1,05 -1,42
Operating Income -0,04 0,02 -0,03 -0,04 -0,05
Operating Margin % -737,61% 256,94% -482,09% -347,54% -382,65%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -31,00 26,00 -20,00 -28,00 -47,00
Capital Expenditures 0,00 0,00 -2,00 0,00 -1,00
Free Cash Flow -31,00 26,00 -22,00 -28,00 -47,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 91,09 124,28 91,44 116,69 149,17 191,63
Long Term Assets 23,78 26,15 30,20 62,25 71,55 79,52
Total Assets 114,86 150,44 121,64 178,95 220,71 271,15
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 9,55 17,08 11,78 8,93 12,70 12,38
Long Term Liabilities 0,04 0,08
Total Liabilities 11,82 9,01
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings -19,85 -163,55 -186,33 -126,07 -88,14 -36,79
Treasury Stock
Total Stockholder Equity 104,89 132,63 109,82 169,94 208,01 258,77
Net Tangible Assets 84,44 109,03 83,91 111,65 143,04 186,98